Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer

作     者：Stefan Heinrich 

作者机构：General Visceral and Transplantation Surgery University Hospital of Mainz 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2019年第18卷第4期

页      面：305-306页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Surgery mortality operative 

摘      要：Surgery is the standard therapy for pancreatic ductal adenocarcinoma(PDAC).After the dramatic decline of operative mortality over the past decades,the indications for pancreas resections have been continuously extended:currently resections of the portal/superior mesenteric vein are considered standard by many centers,and even arterial resections are under *** these changes,different expert groups have defined resectability criteria containing a grey zone(“borderline resectable disease)of tumors,which may be technically resectable with appropriate surgical expertise,but resection inherits an increased risk of an R1-resection[1].